All News
Children With IBD Showed Impaired Growth Before Diagnosis
(MedPage Today) -- Children who were diagnosed with inflammatory bowel disease (IBD) showed a decline in height, weight, and body mass index (BMI) in the years before diagnosis, particularly those wi
Read MoreSkin is in: as sales of thong bikinis rise, is body confidence also growing?
A Sydney council’s ban on ‘inappropriate’ swimwear stirs a wider debate over complex feelings about women’s bottomsWhen it comes to clothing advice for women, the “rules” are endless.
Read MoreMassachusetts Cuts Residency Requirement for IMGs
(MedPage Today) -- Massachusetts has passed a law that drops residency requirements for international medical graduates (IMGs) and provides an alternative pathway to permanent licensure.
Read MoreMedPod Today: 'Medical Freedom'; More Private Equity Harms; USMLE Cheating Scandal
(MedPage Today) -- The following is a transcript of the podcast episode: Rachael Robertson: Hey everybody.
Read MoreSTAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Read MoreOzempic/Wegovy and 14 Other Drugs Selected for Medicare Price Negotiation
(MedPage Today) -- The blockbuster diabetes and weight-loss drug semaglutide (Ozempic, Rybelsus, Wegovy) along with therapies for asthma, cancers, and various other conditions were among the 15 drugs
Read More'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
(MedPage Today) -- Note that some links may require registration or subscription. Also note that MedPage Today will be closed Monday in observance of Martin Luther King Jr. Day.
Read MoreThe biotech news stories we’re keeping an eye on
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey! This is Meghana.
Read MoreSTAT+: High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.
Read MoreSTAT+: Pharmalittle: We’re reading about Medicare plans to negotiate obesity-drug prices, a Novartis 340B lawsuit, and more
Medicare announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy
Read More